Welcome to LookChem.com Sign In|Join Free
  • or
4-benzyloxy-2-iodo-3-methoxybenzoic acid is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1325207-38-2

Post Buying Request

1325207-38-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1325207-38-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1325207-38-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,2,5,2,0 and 7 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1325207-38:
(9*1)+(8*3)+(7*2)+(6*5)+(5*2)+(4*0)+(3*7)+(2*3)+(1*8)=122
122 % 10 = 2
So 1325207-38-2 is a valid CAS Registry Number.

1325207-38-2Relevant academic research and scientific papers

Synthesis of new tetracyclic 7-oxo-pyrido[3,2,1-de]acridine derivatives

Chen, Ching-Huang,Lin, Yi-Wen,Kakadiya, Rajesh,Kumar, Amit,Chen, Yu-Ting,Lee, Te-Chang,Su, Tsann-Long

, p. 5883 - 5893 (2011)

A series of (±)3-hydroxyl- and 2,3-dihydroxy-2,3-dihydro-7- oxopyrido[3,2,1-de]acridines were synthesized for antitumor evaluation. These agents can be considered as analogues of glyfoline or (±)1,2- dihydroxyacronycine derivatives. The key intermediates,

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN

-

, (2022/05/02)

Bifunctional compounds, which find utility as modulators of androgen receptor (AR), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds AR, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1325207-38-2